Even though multiple studies describe the predictive/prognostic value of these biomarkers in CRC‐targeted therapies and overall survival, there is no significant evidence to recommend selected treatments for mutations in PIK3CA and FBXW7. The gene discussed is PIK3CA; the disease is colorectal carcinoma.